Bg pattern

ETALPHA 2 micrograms/ml ORAL DROPS IN SOLUTION

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use ETALPHA 2 micrograms/ml ORAL DROPS IN SOLUTION

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the User

Etalpha2 micrograms/ml oral drops in solution

alfacalcidol

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

  1. What Etalpha is and what it is used for
  2. What you need to know before you take Etalpha
  3. How to take Etalpha
  4. Possible side effects
  5. Storage of Etalpha
  6. Contents of the pack and further information

1. What Etalpha is and what it is used for

Etalpha belongs to a group of medicines called vitamin D analogues that regulate calcium and phosphorus levels in your body.

The active substance of Etalpha is alfacalcidol, a form of vitamin D.

Alfacalcidol works by being converted into calcitriol (the active form of vitamin D) in the liver.

The medicine is indicated in situations where there is an alteration of calcium and phosphorus metabolism due to reduced production of 1,25-dihydroxyvitamin D.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you take Etalpha

Do not take Etalpha

  • if you are allergic to alfacalcidol or any of the other ingredients of this medicine (listed in section 6).
  • if you have high levels of calcium in your blood (hypercalcaemia).

As during treatment with Etalpha, high levels of calcium in your blood (hypercalcaemia) may appear, you should know the following signs and symptoms of hypercalcaemia:

  • loss of appetite (anorexia)
  • fatigue
  • nausea
  • vomiting
  • constipation or diarrhoea
  • increased urine production
  • sweating
  • headache
  • thirst
  • high blood pressure
  • drowsiness
  • dizziness

Warnings and precautions

Consult your doctor or pharmacist before taking Etalpha.

Be particularly careful with Etalpha if:

  • you have arteriosclerosis, cardiac valve sclerosis, or kidney stones (nephrolithiasis). These conditions may worsen if you have high levels of calcium in your blood (hypercalcaemia).
  • you suffer from lung tissue calcification.
  • you have renal bone disease or any kidney disorder. To maintain acceptable serum phosphorus levels, phosphorus binders may be used.
  • you have inflammatory diseases such as sarcoidosis. These conditions have the potential to increase sensitivity to Etalpha.
  • you are being treated with heart medications (cardiac glycosides). If the level of calcium in your blood increases too much (hypercalcaemia), the use of these medications can cause changes in your heart rhythm.

During treatment, your doctor will perform blood tests to monitor calcium and phosphorus levels.

Using Etalpha with other medicines

Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.

It is important that you inform your doctor if:

  • you are being treated with diuretics, calcium-containing preparations, or other vitamin D-containing preparations, as these may increase the risk of elevated calcium levels in your blood (hypercalcaemia).
  • you are being treated with anti-epileptic medications (barbiturates, phenytoin, carbamazepine, or primidone). You may require a higher dose of Etalpha.
  • you are taking antacids containing magnesium, as these may increase the risk of high magnesium levels in your blood (hypermagnesaemia).
  • you are being treated with aluminium-containing preparations (such as aluminium hydroxide or sucralfate), as this may increase aluminium absorption.
  • you are taking bile acid sequestrants such as cholestyramine at the same time as Etalpha, as this may alter the intestinal absorption of Etalpha. To reduce the possibility of interference, alfacalcidol should be administered at least 1 hour before or 4-6 hours after ingestion of bile acid sequestrants.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, consult your doctor or pharmacist before using this medicine.

Etalpha may be used during pregnancy and breastfeeding only when your doctor considers it essential.

Consult your doctor or pharmacist before using any medicine.

Driving and using machines

The influence of Etalpha on the ability to drive and use machines is negligible.

However, dizziness may occur during treatment, which you should take into account if you drive or use machines.

Etalpha contains ethanol, sorbitol, macrogolglycerol hydroxystearate, and methyl parahydroxybenzoate

This medicine contains up to 113 mg of alcohol (ethanol) in each dose (corresponding to 2 micrograms of alfacalcidol), which is equivalent to 14% ethanol (alcohol). The amount in each dose of this medicine is equivalent to less than 3 ml of beer or 1.5 ml of wine.

The small amount of alcohol in this medicine does not produce any noticeable effect.

This medicine contains 452 mg of sorbitol in each ml, equivalent to 6.5 mg sorbitol/kg/day for an adult (70 kg). Sorbitol is a source of fructose. If your doctor has told you that you (or your child) have an intolerance to some sugars, or have been diagnosed with hereditary fructose intolerance (HFI), a rare genetic disorder in which the patient cannot break down fructose, consult your doctor before taking this medicine.

This medicine may cause stomach upset and diarrhea because it contains macrogolglycerol hydroxystearate.

It may cause allergic reactions (possibly delayed) because it contains methyl parahydroxybenzoate.

This medicine contains less than 23 mg of sodium (1 mmol) per ml; it is essentially "sodium-free".

3. How to take Etalpha

Follow exactly the administration instructions of this medicine given by your doctor. If you are unsure, consult your doctor or pharmacist again.

1 ml or 20 drops of Etalpha oral drops in solution are equivalent to 2 micrograms of alfacalcidol (1 drop is equivalent to 0.1 micrograms of alfacalcidol).

Adults and children over 20 kg in weight:

The initial dose is 1 microgram (0.5 ml) per day, i.e., 10 drops per day.

Children under 20 kg in weight:

The initial dose is 0.05 micrograms per kg of body weight per day.

The maintenance dose is usually between 0.25 and 1 microgram per day.

Your doctor may adjust these doses according to your needs. To do this, your doctor may perform blood tests or request other diagnostic tests.

If you take more Etalpha than you should

If you have taken too much Etalpha, contact your doctor or pharmacist.

An overdose can lead to high levels of calcium in your blood and urine. Therefore, your doctor may need to perform tests.

In case of overdose or accidental ingestion, consult the Toxicological Information Service, telephone 91 562 04 20, indicating the medicine and the amount used.

If you forget to take Etalpha

Do not take a double dose to make up for forgotten doses. Continue according to the prescribed dosage.

If you stop taking Etalpha

Your doctor will indicate the duration of your treatment with Etalpha. Do not stop treatment before this, as it may be harmful to your health.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Common side effects (may affect up to 1 in 10 people):

  • high levels of calcium in the blood
  • excessive phosphorus in the blood
  • abdominal pain and discomfort
  • skin rash
  • itching
  • excess calcium in the urine

Uncommon side effects (may affect up to 1 in 100 people):

  • confusion
  • headache
  • diarrhea
  • vomiting
  • constipation
  • nausea
  • muscle pain
  • worsening of kidney function (including acute kidney failure)
  • kidney stones
  • calcium deposits in the kidneys
  • fatigue
  • tiredness
  • malaise
  • calcium deposits in non-osseous tissues

Rare side effects (may affect up to 1 in 1000 people):

  • dizziness

Reporting of side effects

If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly to the Spanish Medicines and Healthcare Products Agency (AEMPS) via their website: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Etalpha

Keep this medicine out of the sight and reach of children.

Store in a refrigerator (between 2°C and 8°C).

Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date is the last day of the month stated.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.

6. Contents of the pack and further information

Composition of Etalpha

  • The active substance is alfacalcidol.

1 ml of solution (20 drops) contains 2 micrograms of alfacalcidol.

  • The other ingredients are sorbitol (E-420), ethanol, macrogolglycerol hydroxystearate, sodium citrate, methyl parahydroxybenzoate (E-218), citric acid monohydrate, all-rac-α-tocopherol, and purified water.

Appearance of the product and pack contents

Colourless, transparent or slightly opalescent solution.

Etalpha oral drops in solution are presented in a 10 ml amber glass bottle with a dosing dropper.

Marketing authorisation holder

CHEPLAPHARM Arzneimittel GmbH

Ziegelhof 24

17489 Greifswald

Germany

Local representative

Laboratorios Rubió, S.A.

Industria, 29 – Pol. Ind. Comte de Sert

08755 Castellbisbal (Barcelona)

Spain

Manufacturer

LEO Pharma A/S

Industriparken 55

DK-2750 Ballerup

Denmark

Date of last revision of this leaflet: January 2022

Detailed and up-to-date information on this medicine is available on the website of the Spanish Agency for Medicines and Healthcare Products (AEMPS) http://www.aemps.gob.es/.

Online doctors for ETALPHA 2 micrograms/ml ORAL DROPS IN SOLUTION

Discuss questions about ETALPHA 2 micrograms/ml ORAL DROPS IN SOLUTION, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (17)
Doctor

Anastasiia Shalko

Family medicine 13 years exp.

Dr. Anastasiia Shalko is a general practitioner with a background in both paediatrics and general medicine. She graduated from Bogomolets National Medical University in Kyiv and completed her paediatric internship at the P.L. Shupyk National Medical Academy of Postgraduate Education. After working as a paediatrician in Kyiv, she relocated to Spain, where she has been practising general medicine since 2015, providing care for both adults and children.

Her work focuses on urgent, short-term medical concerns – situations where patients need quick guidance, symptom assessment and clear next steps. She helps people understand whether their symptoms require in-person evaluation, home management or a change in treatment. Common reasons for booking an online consultation include:

  • acute respiratory symptoms (cough, sore throat, runny nose, fever)
  • viral illnesses such as colds and seasonal infections
  • gastrointestinal complaints (nausea, diarrhoea, abdominal pain, gastroenteritis)
  • sudden changes in how a child or adult feels
  • questions about existing treatment and whether adjustments are needed
  • renewal of prescriptions when clinically appropriate
Dr. Shalko works specifically with urgent and short-term problems, providing practical recommendations and helping patients determine the safest next step. She explains symptoms clearly, guides patients through decision-making and offers straightforward medical advice for everyday acute issues.

She does not provide long-term management of chronic conditions, ongoing follow-up or comprehensive care plans for complex long-term illnesses. Her consultations are designed for acute symptoms, sudden concerns and situations where timely medical input is important.

With clinical experience in both paediatrics and general medicine, Dr. Shalko confidently supports adults and children. Her communication style is clear, simple and reassuring, helping patients feel informed and supported throughout the consultation.

Camera Book a video appointment
€50
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for ETALPHA 2 micrograms/ml ORAL DROPS IN SOLUTION?
ETALPHA 2 micrograms/ml ORAL DROPS IN SOLUTION requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in ETALPHA 2 micrograms/ml ORAL DROPS IN SOLUTION?
The active ingredient in ETALPHA 2 micrograms/ml ORAL DROPS IN SOLUTION is alfacalcidol. This information helps identify medicines with the same composition but different brand names.
Who manufactures ETALPHA 2 micrograms/ml ORAL DROPS IN SOLUTION?
ETALPHA 2 micrograms/ml ORAL DROPS IN SOLUTION is manufactured by Cheplapharm Arzneimittel Gmbh. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of ETALPHA 2 micrograms/ml ORAL DROPS IN SOLUTION online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether ETALPHA 2 micrograms/ml ORAL DROPS IN SOLUTION is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to ETALPHA 2 micrograms/ml ORAL DROPS IN SOLUTION?
Other medicines with the same active substance (alfacalcidol) include ETALPHA 1 microgram INJECTABLE SOLUTION, ETALPHA 2 micrograms INJECTABLE SOLUTION, ALDEXINA 25,000 IU HARD CAPSULES. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media